Alle Fälle anzeigen
UPC APP 11261/2025
—·EP2401365: REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION
- Verfahrensdetails
- Status—VerfahrensartVorbescheidKategorieVorab-Einrede
- Parteien
- Beklagte
- BioNTech SE
- BioNTech Manufacturing GmbH
- BioNTech Manufacturing Marburg GmbH
- BioNTech Innovative Manufacturing Services GmbH
- BioNTech Europe GmbH
- Pfizer Manufacturing Belgium NV
- Pfizer SAS
- Pfizer AB
- Pfizer, Inc.
Vertreter: Christine Kanz (Hoyng Rokh Monegier); Tobias J. Hessel (Clifford Chance) - Division
- Munich LD
- Richter
- Andras Kupecz · Judge-rapporteur
- Technology
- Biotechnology
- Sprache
- —
- Erste Entscheidung
- 17. Apr. 2025
Entscheidungen
- 2025-04-17ZuständigkeitPreliminary objection
The Local Division Munich ruled on preliminary objections filed by BioNTech and Pfizer entities challenging UPC jurisdiction over Comirnaty COVID-19 vaccine variants sold before 1 June 2023, addressing the UPC's temporal jurisdiction in relation to the opt-out regime and the date of UPC operation.
Rechtsfragen:Preliminary objection – jurisdiction (R.19 RoP)Temporal jurisdiction of UPCOpt-out regimeCOVID-19 vaccine infringement claim
Dokumente
- 461EA1D1D0D9579BEC10A6A7C20AE019_en.pdf2025-04-17EN